J
Jee Hyun Kim
Researcher at Seoul National University Bundang Hospital
Publications - 703
Citations - 12600
Jee Hyun Kim is an academic researcher from Seoul National University Bundang Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 46, co-authored 319 publications receiving 9907 citations. Previous affiliations of Jee Hyun Kim include Seoul National University & New Generation University College.
Papers
More filters
Journal ArticleDOI
Metastatic gastric carcinoma in a 19-year-old man.
Yun Hyi Ku,Keun-Wook Lee,Jee Hyun Kim,Hyoungsuk Ko,Hye Seung Lee,Gheeyoung Choe,Young Hoon Kim +6 more
Journal ArticleDOI
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
Ji-Yeon Kim,Seock-Ah Im,Kyung Hae Jung,Jungsil Ro,Joohyuk Sohn,Jee Hyun Kim,Yeon Hee Park,Tae Yong Kim,Sung-Bae Kim,Keun Seok Lee,Gun Min Kim,Se Hyun Kim,Seonwoo Kim,Jin Seok Ahn,Kyung-Hun Lee,Jin-Hee Ahn,In Hae Park,Young-Hyuck Im +17 more
TL;DR: F + G provides a promising new option for the treatment of premenopausal women with HR+, HER2-, tamoxifen-pretreated MBC and there were no TTP differences according to treatment arm.
Journal ArticleDOI
Practical Outcome of Adjuvant FOLFOX4 Chemotherapy in Elderly Patients with Stage III Colon Cancer: Single-center Study in Korea
Jiyeon Kim,Yu Jung Kim,Keun-Wook Lee,Jong Seok Lee,Duck-Woo Kim,Sung Bum Kang,Hye Seung Lee,Na Young Jang,Jae Sung Kim,Jee Hyun Kim +9 more
TL;DR: Adjuvant oxaliplatin, fluorouracil and leucovorin chemotherapy resulted in similar efficacy without significant increase in toxicity in older patients aged ≥65 when compared with younger patients with curatively resected Stage III colon cancer.
Journal ArticleDOI
Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors.
Se Hyun Kim,Jin Won Kim,In Gyu Hwang,Joung Soon Jang,Soojung Hong,Tae Yong Kim,Ji Yeon Baek,Seong Hoon Shin,Der Sheng Sun,Dae Sik Hong,Hyo Jung Kim,Yong Sang Hong,In Sook Woo,Ju Hyun Lee,Jee Hyun Kim +14 more
TL;DR: In older patients with cancer, high serum concentrations of activin A and myostatin were predictive of poor OS, and IL-6 and CRP might be useful to select older patients at risk of early mortality.
Journal ArticleDOI
Patient-reported outcomes of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer: A prospective, open-label, randomized phase ll trial (KCSG-BR 15-10)
Soohyeon Lee,Seock-Ah Im,Gun Min Kim,Kyung Hae Jung,Seok Yun Kang,In Hae Park,Jee Hyun Kim,Kyoung Eun Lee,Hee Kyung Ahn,Moon Hee Lee,Hee Jun Kim,Han Jo Kim,Jong In Lee,Su Jin Koh,Yeon Hee Park +14 more
TL;DR: It is reported that palbociclib plus exemestane with ovarian function suppression (with leuprolide) led to significantly longer median progression-free survival compared with capecitabine in premenopausal metastatic breast cancer patients.